Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4620077 | 0.88 | — | — | |
| SCHEMBL27524137 | 0.84 | LMNA (0.39) | TSHRSMN1; SMN2 | |
| SCHEMBL27676179 | 0.81 | TSHR (0.50) | TSHRSMN1; SMN2 | |
| SCHEMBL20658082 | 0.78 | TSHR (0.33) | TSHR | |
| SCHEMBL10928473 | 0.73 | TSHR (0.39) | TSHRSMN1; SMN2 | |
| SCHEMBL4269748 | 0.72 | TSHR (0.33) | TSHRSMN1; SMN2 | |
| SCHEMBL498637 | 0.72 | — | — | |
| SCHEMBL27686774 | 0.72 | TSHR (0.41) | TSHRSMN1; SMN2 | |
| SCHEMBL545145 | 0.71 | TSHR (0.58) | TSHRSMN1; SMN2 | |
| SCHEMBL57057 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1039325-C | Substituted isoxazolidines and isoxazolines | PHARMACIA AB (SE) | 1998-07-29 | — | — | CN | claimed |
| EP-3169671-A1 | SUBSTITUTED UREA DERIVATIVES AND PHARMACEUTICAL USES THEREOF | Sunshine Lake Pharma Co., Ltd. (CN) | 2017-05-24 | — | — | EP | disclosed |
| WO-2016008433-A1 | SUBSTITUTED UREA DERIVATIVES AND PHARMACEUTICAL USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-01-21 | — | — | WO | disclosed |
| WO-2015043492-A1 | SUBSTITUTED UREA DERIVATIVES AND USES THEREOF IN MEDICINE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-04-02 | — | — | WO | disclosed |
| US-20100143273-A1 | COSMETIC COMPOSITION COMPRISING AT LEAST ONE APROTIC HYDROCARBON-BASED VOLATILE SOLVENT | L'OREAL S.A. (FR) | 2010-06-10 | — | — | US | disclosed |
| EP-2083789-A1 | COSMETIC COMPOSITION COMPRISING AT LEAST ONE APROTIC HYDROCARBON-BASED VOLATILE SOLVENT | L'Oréal (FR) | 2009-08-05 | — | — | EP | disclosed |
| WO-2008061985-A1 | COSMETIC COMPOSITION COMPRISING AT LEAST ONE APROTIC HYDROCARBON-BASED VOLATILE SOLVENT | L'OREAL (FR) | 2008-05-29 | — | — | WO | disclosed |
| US-6995163-B2 | Tricyclic fused heterocyclic compound, process for preparing it and medicament comprising it | EISAI CO., LTD. (JP) | 2006-02-07 | — | — | US | disclosed |
| US-6951865-B2 | Fused heterotricyclic compounds, process for preparing the compounds and drugs containing the same | EISAI CO., LTD. (JP) | 2005-10-04 | — | — | US | disclosed |
| US-6927221-B2 | Tricyclic fused heterocyclic compound, process for preparing it and medicament comprising it | EISAI CO., LTD. (JP) | 2005-08-09 | — | — | US | disclosed |
| US-20050004159-A1 | Tricyclic fused heterocyclic compound, process for preparing it and medicament comprising it | EISAI CO., LTD. | 2005-01-06 | — | — | US | disclosed |
| US-20050004147-A1 | Tricyclic fused heterocyclic compound, process for preparing it and medicament comprising it | EISAI CO., LTD. | 2005-01-06 | — | — | US | disclosed |
| EP-1408040-A1 | Tricyclic fused heterocyclic compounds as CRFantagonists | Eisai Co., Ltd. (JP) | 2004-04-14 | — | — | EP | disclosed |
| US-20030078277-A1 | Fused heterotricyclic compounds, process for preparing the compounds and drugs containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2003-04-24 | — | — | US | disclosed |
| EP-1238979-A1 | FUSED HETEROTRICYCLIC COMPOUNDS, PROCESS FOR PREPARING THE COMPOUNDS AND DRUGS CONTAINING THE SAME | Eisai Co., Ltd. (JP) | 2002-09-11 | — | — | EP | disclosed |
| EP-0426213-B1 | Oral compositions | UNILEVER NV (NL) | 1993-11-03 | — | — | EP | disclosed |
| EP-0426213-A1 | Oral compositions | UNILEVER N.V. (NL) | 1991-05-08 | — | — | EP | disclosed |
| CN-1048218-A | The different azoles alkane and the different oxazoline compound that replace | PHARMACIA AB (SE) | 1991-01-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078277-A1 | Fused heterotricyclic compounds, process for preparing the compounds and drugs containing the same | NR3C2, CRHR1, CRHR2 | TSHR 140/4885SMN1; SMN2 3994/4885 |
| US-20050004159-A1 | Tricyclic fused heterocyclic compound, process for preparing it and medicament comprising it | CRHR2, CRHR1, NR3C2 | TSHR 47/4885SMN1; SMN2 3935/4885 |
| US-20050004147-A1 | Tricyclic fused heterocyclic compound, process for preparing it and medicament comprising it | CRHR2, CRHR1, NR3C2 | TSHR 47/4885SMN1; SMN2 3935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.